17 July 2017

Notice of Results

 

LONDON, 17 July, 2017: Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its interim financial results for the six months ended 30 June 2017 on Monday 31 July 2017.

 

For more information, please contact:

 

Arix Bioscience plc

Joe Anderson, CEO

+44 (0) 20 7290 1052

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com


Back to previous page